Huachao Bin
Overview
Explore the profile of Huachao Bin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
39
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang W, Mu B, You J, Tian C, Bin H, Xu Z, et al.
Nat Commun
. 2022 Dec;
13(1):7473.
PMID: 36463308
Ferroptosis is a new type of programmed cell death characterized by iron-dependent lipid peroxidation. Ferroptosis inhibition is thought as a promising therapeutic strategy for a variety of diseases. Currently, a...
2.
Chen P, Bin H, Jiao Y, Lin G, Zhang Y, Xia A, et al.
Bioorg Med Chem Lett
. 2022 Mar;
63:128651.
PMID: 35245663
Ataxia telangiectasia and Rad3-related (ATR) kinase is a key regulating protein within the DNA damage response (DDR), responsible for sensing replication stress (RS), and has been considered as a potential...
3.
Bin H, Chen P, Wu M, Wang F, Lin G, Pan S, et al.
Eur J Med Chem
. 2022 Feb;
232:114187.
PMID: 35183872
Ataxia telangiectasia mutated and Rad3-related (ATR) kinase is an important regulator of the DNA damage response (DDR), especially in response to replication stress (RS). Tumor cells with ataxia-telangiectasia mutated (ATM)...
4.
Jiao Y, Nan J, Mu B, Zhang Y, Zhou N, Yang S, et al.
Eur J Med Chem
. 2022 Feb;
232:114194.
PMID: 35183871
The NLRP3 inflammasome, which regulated a proinflammatory programmed cell death form termed pyroptosis, is involved in the pathological process of various human diseases, such as multiple sclerosis, type 2 diabetes,...
5.
Pan S, Zhang L, Luo X, Nan J, Yang W, Bin H, et al.
J Med Chem
. 2022 Jan;
65(3):2035-2058.
PMID: 35080890
Tropomyosin receptor kinases (TrkA, TrkB, and TrkC) are attractive therapeutic targets for multiple cancers. Two first-generation small-molecule Trks inhibitors, larotrectinib and entrectinib, have just been approved to use clinically. However,...